Gala Pharmaceutical Inc.: 10-Q filed 2012-04-23
What Gala Pharmaceutical Inc. reported in its quarterly report filed 2012-04-23 (fiscal Q1 2012): 14 published measures, 31 facts as tagged in accession 0001014897-12-000086.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2012-04-23
- Fiscal period
- fiscal Q1 2012
- Accession
- 0001014897-12-000086 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Gala Pharmaceutical Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-02-29 | 1,172 | USD | |
| At 2011-11-30 | 4,134 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-02-29 | 100 | USD | |
| At 2011-11-30 | 100 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-02-29 | 1,072 | USD | |
| At 2011-11-30 | 4,034 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-12-01 to 2012-02-29 | -2,962 | USD | 91 |
| 2010-03-15 to 2012-02-29 | -23,028 | USD | 717 |
| 2010-12-01 to 2011-02-28 | -6,141 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-12-01 to 2012-02-29 | -2,844 | USD | 91 |
| 2010-03-15 to 2012-02-29 | -22,337 | USD | 717 |
| 2010-12-01 to 2011-02-28 | -6,141 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2010-03-15 to 2012-02-29 | 24,100 | USD | 717 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2010-03-15 to 2012-02-29 | -1,420 | USD | 717 |
| 2010-12-01 to 2011-02-28 | -1,420 | USD | 90 |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-12-01 to 2012-02-29 | 5,860,000 | shares | 91 |
| 2010-12-01 to 2011-02-28 | 5,860,000 | shares | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-02-29 | 343 | USD | |
| At 2011-11-30 | 3,187 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-02-29 | 100 | USD | |
| At 2011-11-30 | 100 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-12-01 to 2012-02-29 | 2,962 | USD | 91 |
| 2010-03-15 to 2012-02-29 | 23,028 | USD | 717 |
| 2010-12-01 to 2011-02-28 | 6,141 | USD | 90 |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-02-29 | 18,240 | USD | |
| At 2011-11-30 | 18,240 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-12-01 to 2012-02-29 | 2,844 | USD | 91 |
| 2010-03-15 to 2012-02-29 | 22,437 | USD | 717 |
| 2010-12-01 to 2011-02-28 | 6,141 | USD | 90 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-12-01 to 2012-02-29 | 118 | USD | 91 |
| 2010-03-15 to 2012-02-29 | 591 | USD | 717 |
Inspect the source
- Entity
- Gala Pharmaceutical Inc. / CIK 0001513403
- Captured
- SEC response SHA-256
3d1db4681c9d9a4cd1ba58e701ccbc4c56e8be5f9d6000e0517ef1300b358a33
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001513403.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))